Citigroup’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $215K | Sell |
|
|||||
|
2025
Q2 | $1.31M | Sell |
|
|||||
|
2025
Q1 | $2.64M | Buy |
|
|||||
|
2024
Q4 | $2.08M | Buy |
|
|||||
|
2024
Q3 | $1.16M | Buy |
|
|||||
|
2024
Q2 | $723K | Sell |
|
|||||
|
2024
Q1 | $11.6M | Buy |
|
|||||
|
2023
Q4 | $7.15M | Buy |
|
|||||
|
2023
Q3 | $2.63M | Buy |
|
|||||
|
2023
Q2 | $2.48M | Sell |
|
|||||
|
2023
Q1 | $5.5M | Buy |
|
|||||
|
2022
Q4 | $3.92M | Sell |
|
|||||
|
2022
Q3 | $5.98M | Buy |
|
|||||
|
2022
Q2 | $4.29M | Buy |
|
|||||
|
2022
Q1 | $1.09M | Sell |
|
|||||
|
2021
Q4 | $5.39M | Buy |
|
|||||
|
2021
Q3 | $2.33M | Sell |
|
|||||
|
2021
Q2 | $4.77M | Sell |
|
|||||
|
2021
Q1 | $3.68M | Buy |
|
|||||
|
2020
Q4 | $554K | Buy |
|
|||||
|
2020
Q3 | $242K | Sell |
|
|||||
|
2020
Q2 | $1.49M | Buy |
|
|||||
|
2020
Q1 | $288K | Sell |
|
|||||
|
2019
Q4 | $688K | Sell |
|
|||||
|
2019
Q3 | $1.05M | Sell |
|
|||||
|
2019
Q2 | $1.44M | Buy |
|
|||||
|
2019
Q1 | $219K | Sell |
|
|||||
|
2018
Q4 | $1.94M | Buy |
|
|||||
|
2018
Q3 | $953K | Buy |
|
|||||
|
2018
Q2 | $491K | Sell |
|
|||||
|
2018
Q1 | $662K | Sell |
|
|||||
|
2017
Q4 | $764K | Buy |
|
|||||
|
2017
Q3 | $148K | Sell |
|
|||||
|
2017
Q2 | $398K | Buy |
|
|||||
|
2017
Q1 | $28K | Sell |
|
|||||
|
2016
Q4 | $172K | Buy |
|
|||||
|
2016
Q3 | $10K | Sell |
|
|||||
|
2016
Q2 | $61K | Sell |
|
|||||
|
2016
Q1 | $157K | Buy |
|
|||||
|
2015
Q4 | $257K | Sell |
|
|||||
|
2015
Q3 | $703K | Buy |
|
|||||
|
2015
Q2 | $423K | Sell |
|
|||||
|
2015
Q1 | $286K | Sell |
|
|||||
|
2014
Q4 | $389K | Buy |
|
|||||
|
2014
Q3 | $68K | Sell |
|
|||||
|
2014
Q2 | $115K | Buy |
|
|||||
|
2014
Q1 | $91K | Buy |
|
|||||
|
2013
Q4 | $50K | Buy |
|
|||||
|
2013
Q3 | $15K | Sell |
|
|||||
|
2013
Q2 | $3K | Buy |
|